ARDX - חוב כולל להון Ardelyx Corp

The current debt-to-equity ratio visualizes the financial leverage of Ardelyx, Inc. (ARDX), with the value 1.82 reflecting the current level of leverage. Ardelyx, Inc. (ARDX) management has demonstrated resilience in pursuing approval for its flagship product, aiming to capture the nephrology market. The company is investing in R&D to develop molecules that regulate ion exchange. The business relies on independent drug launches, limiting partnerships to targeted licensing outside the US.

Ardelyx, Inc. maintains a stable staff of nephrologists and researchers, which minimizes operational risks during business scaling. Investments in human capital require a balance between debt and equity financing. This ratio measures the proportion of total liabilities relative to equity, determining the degree of dependence on creditors. A low value protects the company from interest rate shocks, whereas excessive leverage increases the risk of default. By analyzing the company's leverage history, an investor assesses the stability of the balance sheet.